Apolipoprotein E genotype and in vivo amyloid burden in middle-aged Hispanics.
| Publication Type | Academic Article |
| Authors | Palta P, Rippon B, Reitz C, He H, Sherwood G, Ceballos F, Teresi J, Razlighi Q, Moreno H, Brickman A, Luchsinger J |
| Journal | Neurology |
| Volume | 95 |
| Issue | 15 |
| Pagination | e2086-e2094 |
| Date Published | 08/26/2020 |
| ISSN | 1526-632X |
| Keywords | Amyloid, Apolipoprotein E4, Brain, Hispanic or Latino |
| Abstract | OBJECTIVE: To examine in vivo amyloid burden in relation to APOEε4 genotype in middle-aged Hispanics. We hypothesize higher amyloid levels among APOE ε4 carriers vs APOE ε4 noncarriers. METHODS: This is a cross-sectional study in a community-based sample of 249 middle-aged Hispanics in New York City who underwent a 3T brain MRI and PET with the amyloid radioligand 18F-florbetaben. APOE genotype was the primary exposure. The primary outcome was amyloid positivity. The secondary outcome was subthreshold amyloid levels examined as a continuous variable. RESULTS: APOE ε4 carriers (n = 85) had a higher frequency (15.3%) of amyloid positivity compared to APOE ε4 noncarriers (n = 164, 1.8%). In the subthreshold group of amyloid-negative participants (n = 233), APOE ε4 carriers (n = 72) had a 0.02 (95% confidence interval [CI] 0.01-0.04) higher global brain amyloid standardized uptake value ratio (SUVR) compared to APOE ε4 noncarriers (n = 161). Compared to participants with the ε3/ε3 genotype, participants with ε4/ε4 had the highest frequency of amyloid positivity (28.6%), followed by those with ε3/ε4 (11%). Among amyloid-negative participants (n = 233), compared to participants with ε3/ε3 (n = 134), those with ε4/ε4 (n = 5) had a 0.12 (95% CI 0.07-0.17) higher global brain amyloid SUVR, and those with ε3/ε4 had a 0.02 higher SUVR (95% CI 0.003-0.04). Results were similar when a median split was used for elevated amyloid, when continuous amyloid SUVR was analyzed in all participants, and in nonparametric Mann-Whitney comparisons. CONCLUSION: Middle-aged Hispanic APOE ε4 carriers have higher in vivo brain amyloid burden compared with noncarriers, as reported in non-Hispanics. |
| DOI | 10.1212/WNL.0000000000010707 |
| PubMed ID | 32847955 |
| PubMed Central ID | PMC7713748 |